BIDE Pharmatech 毕得医药
18 significant filings since 31 May 2026: 1 on change of control, 6 on equity incentive and 6 on change of interest, and 3 other kinds. The latest, on 28 Sep 2026: 国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司首次公开发行股票募投项目结项并将节余募集资金及剩余超募资金永久补充流动资金的核查意见.
自 31 May 2026 起有 18 份重大公告：change of control 1 份、equity incentive 6 份、change of interest 6 份，另有 3 类。最新一份（28 Sep 2026）：国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司首次公开发行股票募投项目结项并将节余募集资金及剩余超募资金永久补充流动资金的核查意见。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 余汝意,石启正 | Buy 买入 | 7 May 2026 | 2 | — |
| 太平洋 | 周豫,张崴 | Buy 买入 | 1 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。